NCT00364182 - Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions

Hemophilia B

Interventions

DRUG

Recombinant Coagulation Factor IX (BeneFIX)

100 IU/kg once weekly then crossover to 50 IU/kg twice weekly

DRUG

Recombinant Coagulation Factor IX (BeneFIX)

50 IU/kg twice weekly then crossover to 100 IU/kg once weekly

Trial Locations (19)

1134

Pfizer Investigational Site, Budapest

10000

Pfizer Investigational Site, Zagreb

11000

Pfizer Investigational Site, Belgrade

18000

Pfizer Investigational Site, Niš

28046

Pfizer Investigational Site, Madrid

31033

Pfizer Investigational Site, Castelfranco Veneto (TV)

41013

Pfizer Investigational Site, Seville

60614

Pfizer Investigational Site, Chicago

67100

Pfizer Investigational Site, Coppito (AQ)

85016

Pfizer Investigational Site, Phoenix

125167

Pfizer Investigational Site, Moscow

191186

Pfizer Investigational Site, Saint Petersburg

60612-3833

Pfizer Investigational Site, Chicago

08903-0019

Pfizer Investigational Site, New Brunswick

77030-4009

Pfizer Investigational Site, Houston

T6G 2B7

Pfizer Investigational Site, Edmonton

T6G 2C8

Pfizer Investigational Site, Edmonton

K1H 8L6

Pfizer Investigational Site, Ottawa

011155

Pfizer Investigational Site, Bucharest